From HCV Partner To Acquirer, BMS Makes $885 M Offer for ZymoGenetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Ever since its pure-play biopharma strategy went into effect, Bristol-Myers Squibb has preferred buying biotechs it knows well. Hepatitis C development partner ZymoGenetics is no exception.
You may also be interested in...
First Quarter Updates, In Brief
Launch news was an important factor for Bristol-Myers in the first quarter and dominated the biotech sector, with several companies reporting better-than-expected early performances of new products, although for Lilly, the news was all about upcoming data read-outs.
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.
Biogen Continues To Plot New Course In Naming Two Key Executives – But Is Independence Part Of The Plan?
Since his arrival as CEO nearly seven months ago, Biogen Idec Inc.’s George Scangos has been exerting his influence in ways both big and small. None may have more lasting impact than his recruitment of two top industry executives, Steven Holtzman and Doug Williams, to take the reins respectively as Biogen’s executive VP of corporate development and executive VP of R&D.